advanced non-small cell lung cancer
Conditions
Interventions
We perform FMISO-PET before and 8 weeks after immune checkpoint inhibitor treatment
Sponsors
Saitama Medical University International Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Patients diagnosed with advanced non-small cell lung cancer 2. Patients who are scheduled to be treated with immune checkpoint inhibitors (anti-PD-1/PD-L1 antibodies) 3. Patients over the age of 20 when consent is obtained 4.Patients undergoing FDG-PET for whole body search 5. Patients with measurable lesions 6. Patients who have major organ functions 7. Patients who have obtained informed consent for this study
Exclusion criteria
Exclusion criteria: 1. Pregnant women, lactating women and women with the possibility or intention of becoming pregnant 2. Patients with complications that require intravenous administration of antibiotics and antifungal agents 3.Patients who need to administer systemic steroids and other immunosuppressive drugs 4. Patients with diabetes 5. In addition, patients who are judged as inappropriate by the doctor's judgment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change of SUVmax, MTV and TLG of FMISO accumulation on PET | — |
Countries
Japan
Contacts
Public ContactKosuke Hashimoto
Saitama Medical University International Medical Center Respiratory medicine
Outcome results
None listed